tradingkey.logo
๎™

Armata Pharmaceuticals Inc

ARMP
6.240USD
+0.080+1.30%
์ข…๊ฐ€ย 12/22, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
226.07M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

Armata Pharmaceuticals Inc

6.240
+0.080+1.30%

์ž์„ธํ•œ ๋‚ด์šฉ์€ Armata Pharmaceuticals Inc ํšŒ์‚ฌ

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Armata Pharmaceuticals Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ ARMP
ํšŒ์‚ฌ ์ด๋ฆ„Armata Pharmaceuticals Inc
์ƒ์žฅ์ผMay 20, 1994
CEOBirx (Deborah L)
์ง์› ์ˆ˜60
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒMay 20
์ฃผ์†Œ5005 Mcconnell Ave
๋„์‹œLOS ANGELES
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX โ€“ NASDAQ Basic Amex
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ90066
์ „ํ™”13106652928
์›น์‚ฌ์ดํŠธhttps://www.armatapharma.com/
์ข…๋ชฉ ์ฝ”๋“œ ARMP
์ƒ์žฅ์ผMay 20, 1994
CEOBirx (Deborah L)

Armata Pharmaceuticals Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Pierre Kyme, Ph.D.
Dr. Pierre Kyme, Ph.D.
Chief Business Officer
Chief Business Officer
2.99K
+509.16%
Dr. Deborah L. Birx, M.D.
Dr. Deborah L. Birx, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Joyce Allaire
Ms. Joyce Allaire
Investor Relations
Investor Relations
--
--
Dr. Joseph M. Patti, Ph.D.
Dr. Joseph M. Patti, Ph.D.
Independent Director
Independent Director
--
--
Dr. Todd C. Peterson, Ph.D.
Dr. Todd C. Peterson, Ph.D.
Independent Director
Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Independent Director
Independent Director
--
--
Dr. Sarah J. Schlesinger, M.D.
Dr. Sarah J. Schlesinger, M.D.
Independent Director
Independent Director
--
--
Mr. Jules A. Haimovitz
Mr. Jules A. Haimovitz
Independent Director
Independent Director
--
--
Ms. Robin C. Kramer
Ms. Robin C. Kramer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David House
Mr. David House
Principal Financial Officer, Senior Vice President - Finance
Principal Financial Officer, Senior Vice President - Finance
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Pierre Kyme, Ph.D.
Dr. Pierre Kyme, Ph.D.
Chief Business Officer
Chief Business Officer
2.99K
+509.16%
Dr. Deborah L. Birx, M.D.
Dr. Deborah L. Birx, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Joyce Allaire
Ms. Joyce Allaire
Investor Relations
Investor Relations
--
--
Dr. Joseph M. Patti, Ph.D.
Dr. Joseph M. Patti, Ph.D.
Independent Director
Independent Director
--
--
Dr. Todd C. Peterson, Ph.D.
Dr. Todd C. Peterson, Ph.D.
Independent Director
Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Independent Director
Independent Director
--
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Nov 17
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Nov 17
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Innoviva Inc
68.88%
The Vanguard Group, Inc.
0.82%
Geode Capital Management, L.L.C.
0.29%
Edgewood Management LLC
0.27%
Pastagia (Mina M.D.)
0.17%
๊ธฐํƒ€
29.58%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Innoviva Inc
68.88%
The Vanguard Group, Inc.
0.82%
Geode Capital Management, L.L.C.
0.29%
Edgewood Management LLC
0.27%
Pastagia (Mina M.D.)
0.17%
๊ธฐํƒ€
29.58%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Corporation
68.88%
Investment Advisor
1.23%
Investment Advisor/Hedge Fund
0.73%
Individual Investor
0.27%
Hedge Fund
0.11%
๊ธฐํƒ€
28.78%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q4
42
758.32K
2.17%
--
2025Q3
43
758.32K
2.22%
+24.50K
2025Q2
44
733.82K
2.16%
-6.55K
2025Q1
42
740.37K
4.05%
-724.52K
2024Q4
45
1.39M
4.14%
+5.16K
2024Q3
45
1.38M
4.34%
-20.83K
2024Q2
44
1.40M
4.38%
-19.96K
2024Q1
45
1.42M
4.03%
-32.91K
2023Q4
46
1.30M
4.04%
+7.01K
2023Q3
47
1.29M
3.73%
+96.20K
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Innoviva Inc
25.08M
69.22%
--
--
Aug 11, 2025
The Vanguard Group, Inc.
260.07K
0.72%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
104.55K
0.29%
-1.29K
-1.22%
Jun 30, 2025
Edgewood Management LLC
100.00K
0.28%
--
--
Jun 30, 2025
Pastagia (Mina M.D.)
61.08K
0.17%
--
--
Apr 17, 2025
Bridgeway Capital Management, LLC
44.68K
0.12%
--
--
Jun 30, 2025
Renaissance Technologies LLC
38.90K
0.11%
+300.00
+0.78%
Jun 30, 2025
State Street Investment Management (US)
40.30K
0.11%
--
--
Jun 30, 2025
Seacrest Wealth Management, LLC
34.95K
0.1%
--
--
Jun 30, 2025
GSB Wealth Management, LLC
30.00K
0.08%
+30.00K
--
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
๋น„์œจ0.01%
iShares Core S&P Total U.S. Stock Market ETF
๋น„์œจ0%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Armata Pharmaceuticals Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Armata Pharmaceuticals Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
Innoviva Inc๋Š” 25.08M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 69.22%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
The Vanguard Group, Inc.๋Š” 260.07K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.72%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Geode Capital Management, L.L.C.๋Š” 104.55K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.29%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Edgewood Management LLC๋Š” 100.00K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.28%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Pastagia (Mina M.D.)๋Š” 61.08K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.17%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Armata Pharmaceuticals Inc์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Armata Pharmaceuticals Inc์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
Innoviva Inc
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.์ž…๋‹ˆ๋‹ค.

Armata Pharmaceuticals Inc(ARMP)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q4 ๊ธฐ์ค€์œผ๋กœ, Armata Pharmaceuticals Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 42๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 758.32K๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 2.17%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q3 ๋Œ€๋น„ -0.04% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Armata Pharmaceuticals Inc์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
-- ๊ธฐ์ค€, Armata Pharmaceuticals Inc์˜ -- ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ --๋กœ ์ „์ฒด ๋งค์ถœ์˜ --%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™